Nuvalent Analyst Upgrades, Targets $130

This is a Nuvalent news story, published by Yahoo Finance, that relates primarily to NUVL news.

Nuvalent news

For more Nuvalent news, you can click here:

more Nuvalent news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Yahoo Finance news

For more news from Yahoo Finance, you can click here:

more news from Yahoo Finance

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

tyrosine kinase inhibitor therapy

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest smart investment decisions news, TKI therapy news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

Smart Value Newsletter

TipRanks

•

Health

Nuvalent price target raised to $130 from $110 at H.C. Wainwright

Summary

Nutrition label

84% Informative

H.C. Wainwright raised the firm’s price target on Nuvalent ( NUVL ) to $ 130 from $ 110 .

The firm says the overall response rate among all patients is 44% , and the patients showed good durability with duration of responses of 78% at 12 months and 62% at 18 months .

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity

Offensive language

not offensive

Hate speech

not hateful